



My ~~C~~ure All


MyCureAll links Patients to Prescribers & Dispensaries & Insurances & Advise them on what strain/strength of medical cannabis and CBD are optimal for their specific conditions.



*Healthcare
Technology
for the
Cannabis Industry*

Management

The Management team is comprised of pharmacists, medical professionals, social workers, and substance abuse and mental health professionals that bring pharmaceutical precision and extensive expertise to the field of medical cannabis.



ELAINE K. RICHER, RPH, Co-Founder & Chief Executive Officer

Ms. Richer, a graduate of Long Island University School of Pharmacy, has been a licensed pharmacist in New Jersey and Florida for over 20 years. Ms. Richer has held leadership roles in three Fortune 500 companies successfully training and managing diverse teams of pharmacists. Ms. Richer is dedicated to providing quality patient care and ensuring improved clinical outcomes.



JACQUES NIR, LCSW, Chief Operations Officer

Jacques Nir, a graduate of Columbia University School of Social Work, is currently director of a mental health clinic and adjunct professor at Columbia University School of Social Work. Mr. Nir has provided quality care as a social worker for 24 years, including serving as director of an outpatient substance abuse program for over 12 years. He has been responsible for multi-million-dollar budgets with OASAS and OMH.



Company



MyCureAll LLC, a New Jersey Limited Liability Company established in 2019, is a Healthcare technology company.



As experts in the pharmaceutical, social work and medical cannabis field, our mission is to properly, consistently, and effectively manage medical cannabis administration by aligning patients, doctors, dispensaries, and insurers to work hand - in - hand for safer and more effective healthcare. In providing a secure and beneficial platform for medical cannabis prescribing as well as CBD, our goal is to bring physical, social and financial relief from the opioid epidemic.



The Management team is comprised of pharmacists, medical professionals, social workers, substance abuse and mental health professionals that bring true clinical precision and extensive expertise to the medical cannabis field.



MYCureAll has built a revolutionary patent pending, HIPAA-compliant platform. The MyCureAll Web Application platform collects protocol information for cannabis as well as our marketed CBD line of pharmacy approved products.



MyCureAll is using the advances in digital healthcare, Artificial Intelligence (AI) and blockchain technology to optimize how to find the best cannabis strain for medical conditions and accelerate the acceptance of the legal cannabis industry into the mainstream healthcare and insurance systems.

Problem

Medical cannabis is being established in the scientific community as a medication of choice, but ***THE CURRENT METHOD OF PRESCRIBING CANNABIS IS INADEQUATE!***

Industry Bottlenecks



Patients spend time and money using a trial and error method to discover what cannabis strain works best to manage their symptoms.



Medical professionals do not know the correct strains and dosing to recommend based on the patient's qualifying condition(s).



Dispensaries are unable to properly manage inventory and recommend a specific strain for a patient's condition(s).



MAT (Medication Assisted Treatment) and Harm Reduction specialists are unable to recommend optimal dosing and strains for clients that present with comorbidities.

The Opioid Epidemic Costs Lives and Money



399,000 people died from opioid overdose from 1999 to 2017.



Annual deaths from opioid overdoses are "projected to reach nearly 82,000 by 2025, resulting in approximately 700,000 deaths from 2016 to 2025.



According to the National Institutes of Health (NIH), substance abuse costs the country over \$600 billion per year.

Solution

The revolutionary Patent Pending My Cure All Web Application platform that:



Patients Able to receive the strain and strength for their medical condition(s), allowing for safer more effective treatment; allows patients to actively participate in their wellness through targeted and consistent treatment plans.



Physicians Receive access to standardized protocols and treatment plans for prescribing medical cannabis based on the patient's condition(s), age, sex, etc.



Dispensaries Able to better manage inventory of various cannabis strains while providing effective care based on patient needs.



Substance Abuse Treatment Providers Able to integrate medical cannabis for opioid dependent clients with MAT treatment.




Insurance Companies Decrease spending on dangerous opioid treatments and subsequent, ineffective opioid addiction rehab programs, by providing effective cannabis usage



Employers Play an active role in providing appropriate healthcare resources to their employees.







Canna-Meter Process™



Natural, Safer, more Effective Symptom Management Solution for Cannabis and CBD Products



Operations



MyCureAll is headquartered in Fair Lawn, New Jersey.

Staffing

MyCureAll is currently operated by its founding members, who manage third party vendors. As the platform grows to new levels, the company will hire budgeted staff for daily operations.



App Purchasing Procedures

All registrations and downloading activity is completed by the MyCureAll WebApp platform.



MyCureAll App

Management of third-party vendors

- Software Development
- Marketing
- Sales
- Customer service

MyCureAll CBD Products

Management of third-party vendors



- Hemp Farmers
- Formulations
- Product Manufacturing
- Packaging
- Website Sales
- Fulfillment
- Customer Service

Market Opportunity



\$41B

U.S. Legal Cannabis

\$8 Billion 2018

\$41 Billion by 2025



\$97B

Global Cannabis

\$10 Billion in 2018

\$ 97 Billion by 2026




\$22B

Global CBD

\$3 Billion in 2018

\$22 billion in 2026



\$31B

**Non-Opioid Pain
Treatments**

\$13.8 Billion in 2019

\$22 Billion in 2024



\$509B

Digital Health

\$95 Billion in 2018

\$509 Billion in 2029

Revenue Streams

App



Physicians



Dispensaries



Products



Retail



Ecommerce



Target Markets



513,000

Current medical marijuana card holders and medical marijuana users by our target states.



9,252,628

Patients currently on a consistent opioid regimen for chronic pain and other conditions.



12,313,725

Patients with chronic conditions or symptoms that are not being managed with other treatments but that can be alleviated with the use of medical cannabis.



767,514

Patients in drug addiction treatment programs that can wean off drugs with the help of cannabis

Market Size

=22,846,867

Approximate total Market Size

of People for NJ, NY, PA, and FL

Sales Process



- *MCA has received state clearance from Department of Health (DOH) and Department of Insurance (DOI)*
- *33 states, Washington D.C., and a number of territories offer medical cannabis as a legal treatment option*



My Cure All App

- App Store Optimization
- Keyword-Rich Description
- Choose Appealing Icon
- Brand Ambassadors
- Channel Partners
- Dispensaries
- Medical Professionals
- Events
- Influencers
- Media
- Sales
- Social Media



My Cure All CBD Products

- Affiliate Marketing
- Brand Ambassadors
- Call Center
- Celebrity Strategy
- Distributor
- Events
- Influencers
- Marketing Partners
- Media
- Medical Professionals
- Online: Amazon
- Retail Stores
- Sales Reps
- SEO:CRM's
- Social Media
- Treatment Facilities
- Videos
- Website

Projected Revenue



2 and 5 Year Financial Projections for MyCureAll States: New Jersey, New York , Pennsylvania and Florida

	FY 2020	FY 2021	FY 2025
Patients signed up on App	66,000	5,000,000	25,000,000
Prescribers signed up on App (MD, RN, DO, PA)	300	1,500	18,000
Targeted Marketing Revenue	\$12,000	\$2,700,000	\$21,000,000
Subscription Revenue Prescribers (\$89)	\$80,100	\$1,602,000	\$19,224,000
Subscription Revenue Dispensaries (\$525)	\$0	\$1,575,000	\$9,450,000
CEU Courses (\$187)		\$106,000	\$1,309,000
CBD Revenue	\$142,700	\$1,205,200	\$8,908,302
Total Revenue	\$234,800	\$7,188,200	\$59,891,302

	FY 2020	FY 2021	FY 2025 (33 states)
Revenue	\$234,800	\$7,188,200	\$59,891,302
Operating Expenses	\$350,000	\$3,987,079	\$6,987,459
EBITDA	(\$115,200)	\$2,796,921	\$52,903,843


PROJECTED REVENUE

3-Year Financial Projections for shopMyCureAll.com/ CBD Line of Products

	FY 2020	FY 2021	FY 2022
Revenue	\$142,700	\$5,545,800	\$18,684,708
Operating Expenses	\$120,000	\$2,097,000	\$6,850,000
EBITDA	\$22,700	\$3,603,000	\$11,834,708

Competition

~~My Cure All~~



Competitive Differentiator



Standardized Set of Protocols

“Canna-Metter” and “Canna-Measure” are our patented technologies that provide the science behind the protocols of medical cannabis



Streamline the Recommendation Process

One stop shopping for the medicinal cannabis patient in order to build claims for insurance coverage.

MyCureAll App Features

- **Assessments: PHQ-9; RODS; GAD; PTSD**
- **Reminder SMS or email for Recommender and Dispensary**
- **“Canna-Measure”: Develop Personalized Treatment Plans**
- **Store 5 PDF Files for Medical and Benefits**
- **Find a dispensary with GPS**
- **Create Insurance Claims**
- **Register with Multiple offices**
- **Validation Protocols**
- **View ICD 10 with Conditions**
- **View insurance Types**
- **List and Schedule Availability**
- **“Canna-Measure” - Treatment Plan: Subjective and Objective Results**
- **“Canna-Meter ” tool: Informed Recommendation Demonstration**
- **Verification Process**
- **Search Patient Population by State, Zip Code, Symptom or Condition with ICD 10 Codes**

Capital Needs & Use of Funds



\$2M

Capital Raise



Structure: Convertible Note

Use of Funds

\$750K

Marketing & Sales

\$500K

Software Development

\$750K

Operations

Exit Strategy

Acquisition, Financial Buyer-Investors, IPO



1. Telemedicine/ Tele-Therapy
2. Expanding our services to the global market
3. Electronic Prescribing System for Cannabis
4. Licensing of Canna- Meter
5. Sale of Data/ Insurance companies
6. MTM (Medication Therapy Management)
7. Growth of targeted medical advertising
8. Social Services/research

Management



Elaine K. Richer, RPH
CEO

Licensed pharmacist in New Jersey and Florida for over 20 years.



Jacques Nir, LCSW
COO

24 years experience in New York State Healthcare Systems.

COLUMBIA
UNIVERSITY



Danny Milhan
MIS Director



Peter Thurlow Esq.
Legal Board Member



Dr. Cynthia C Chirwa
Medical Advisor



Karen Berger, PharmD
Medical Writer



Dr. Mark Duckshtine
Medical Board Member




Christa Rapaport Esq.
Legal Board Member


Disclaimer

This information is not intended to provide complete sales information on a specific product. All investment offers must be preceded or accompanied by a Private Placement Memorandum. Please read it carefully to learn about the risks of investing. Investments in Convertible Notes are highly speculative and may be affected by adverse economic and regulatory changes, among many other risks highlighted a Private Placement Memorandum. This information is not an offer to sell any securities. Such offer may only be made by the Sponsor or its authorized representatives in approved states and to Accredited Investors as defined by SEC Rule 506c.

Thank you



Elaine K. Richer, RPh
CEO



201-470-0337



ericher@mycureall.com




[MyCureAll LinkedIn](#)




Thank you



Jacques Nir,
COO, LCSW



646-662-8431



Jnir@mycureall.com



[MyCureAll LinkedIn](#)